Uncertainty over the Earnings Impact of the Chinese Hospital Operating Business
First written in FY2018-Q1. 8 of 20 entries say "Worsened", first in FY2019-Q3. Latest entry: FY2024.
Nihon Trim moved to the "Worse" side of this theme in 2023, the same year as the typical company in this theme.
The whole theme swung hardest in 2020: 18 of 46 companies on the "Worse" side.
38 other companies' latest entry also says "Worsened".
- FY2024WorsenedAnnual report
「漢琨國際控股有限公司 is an over-indebted company, with negative net worth of ¥4,653 million as of the end of March 2024.」
The China hospital operator’s negative net worth increased from ¥4,150 million at the end of March 2023 to ¥4,653 million. - FY2023WorsenedAnnual report
「漢琨國際控股有限公司 is an over-indebted company, with negative net worth of ¥4,150 million as of the end of March 2023.」
The China hospital operator’s negative net worth increased from ¥3,222 million at the end of March 2022 to ¥4,150 million. - FY2022WorsenedAnnual report
「漢琨國際控股有限公司 is an over-indebted company, with negative net worth of ¥3,222 million as of the end of March 2022.」
The China hospital operator disclosed negative net worth of ¥3,222 million as of the end of March 2022, clarifying the company’s financial exposure. - FY2022-Q3MitigatedAnnual report
「In the hospital business in China, the number of visiting patients has steadily increased since treatment covered by public insurance began in February 2021, and we will continue working with our partners to expand the business toward achieving monthly profitability.」
The company stated that patient numbers have steadily increased since publicly insured medical services began, and that measures to address the previously identified ramp-up and investment recovery risks are progressing. - FY2022-Q1MitigatedAnnual report
「We and Trim Medical Holdings Co., Ltd. agreed to consolidate the receivables we hold from the company, together with receivables held by other partners, and transferred them to a third-party entity in July this year. As a result, quarterly net income attributable to owners of the parent increased by ¥567 million due to lower tax expenses. Negotiations are currently under way with major global corporate groups and others regarding new financing.」
The company stated that receivables from the China hospital operator were transferred to a third-party entity and that negotiations with major global corporate groups and others regarding new financing are progressing. - FY2021MitigatedAnnual report
「Although the increase in the number of patients is slower than expected, partly due to the impact of the COVID-19 pandemic, treatment covered by public insurance began in February this year, and the number of patients has been increasing.」
Although the delay in increasing patient numbers in the China hospital business remains, the company stated that publicly insured medical services have begun and patient numbers are increasing. - FY2021-Q3MitigatedAnnual report
「In the hospital business in China, approval for coverage under public health insurance was granted in November, and preparations are now under way to begin operations.」
The company obtained approval for coverage under public health insurance, one of the previously unresolved factors in the China hospital business, and moved into the preparation phase for the start of operations. - FY2021-Q2MitigatedAnnual report
「The China hospital business has been slow to ramp up, including the rollout of public health insurance coverage, partly due to the COVID-19 pandemic. However, patient numbers are gradually increasing as restrictions on social activity have eased and consumption has recovered, and we believe the business continues to have significant potential. As a loss on the full amount invested was recorded at the end of the previous fiscal year, the business will have no impact on results for the current fiscal year.」
The business remains slow to ramp up, but patient numbers are gradually increasing. The company stated that there will be no impact on current fiscal year results because a loss on the full amount invested was recorded at the end of the previous fiscal year. - FY2021-Q1MitigatedAnnual report
「Although the China hospital business has been affected by the COVID-19 pandemic, we will continue to make steady progress. As a loss on the full amount invested was recorded at the end of the previous fiscal year, this business will have no impact on results for the current fiscal year.」
The China hospital business will continue, while the company stated that there will be no additional impact on current fiscal year results because a loss on the full amount invested was recorded at the end of the previous fiscal year. - FY2020WorsenedAnnual report
「In the China hospital operations, we are working toward full-scale operations while awaiting the delayed approval for coverage under public health insurance. However, in light of the possibility that the COVID-19 pandemic could extend the time required to recover the investment, we decided to record a loss on the full amount invested.」
The company recognized the possibility that delays in public health insurance coverage and the COVID-19 pandemic could extend the investment recovery period, resulting in a loss being recorded on the full amount invested. - FY2020-Q3WorsenedAnnual report
「For the hospital operations in China, we have already applied for coverage under public health insurance and are awaiting approval, while working actively to increase the number of patients. The business remains in the upfront investment phase, and an equity-method investment loss of ¥250 million was recorded as a non-operating expense for the third-quarter consolidated cumulative period.」
The China hospital business was awaiting approval for coverage under public health insurance and remained in the upfront investment phase. The equity-method investment loss reached ¥250 million for the third-quarter cumulative period. - FY2020-Q2WorsenedAnnual report
「The hospital operations in China remain in the upfront investment phase, but we are working diligently toward profitability, including preparations for the start of publicly insured medical services.」
The China hospital operations remain in the upfront investment phase, with an equity-method investment loss of ¥159.691 million recorded for the second-quarter cumulative period. At the same time, preparations are under way for the start of publicly insured medical services. - FY2020-Q1WorsenedAnnual report
「Patient acquisition for the hospital operations in China is behind the initial plan, and the business remains in the upfront investment phase. However, we have signed a contract to provide health management services in partnership with PICC, China’s largest state-owned insurance group, and have obtained eligibility for public health insurance. Publicly insured medical services are expected to begin shortly, and patient acquisition is expected to accelerate significantly. We are making steady progress toward profitability.」
Patient acquisition in the China hospital business lagged the initial plan, and the company recorded an equity-method investment loss of ¥96 million and a foreign exchange loss of ¥46 million in the first quarter. At the same time, measures to increase patient acquisition and achieve profitability are progressing, supported by the PICC partnership and the expected start of publicly insured medical services. - FY2019-Q3WorsenedAnnual report
「We recorded an equity-method investment loss of ¥158 million related to the hospital operations in China as a non-operating expense.」
The equity-method investment loss related to the China hospital operations reached ¥158 million, up from ¥102 million in the previous quarter-to-date period. - FY2019-Q2Equity-method investment loss increased to ¥102 millionAnnual report
「We recorded an equity-method investment loss of ¥102 million related to the hospital operations in China as a non-operating expense.」
For the China hospital operations, an equity-method investment loss of ¥102 million was recorded as a non-operating expense. - FY2019-Q1Equity-method investment loss of ¥59 million recordedAnnual report
「We recorded an equity-method investment loss of ¥59 million related to the hospital operations in China as a non-operating expense.」
For the China hospital operations, we recorded an equity-method investment loss of ¥59 million in the first quarter, following ¥53 million in the previous fiscal year. - FY2018Quantifying the outlook for the earnings impactAnnual report
「The business is expected to begin contributing to Group profits from the fiscal year ending March 2020. During the current consolidated fiscal year, which is the preparation period, we recorded an equity-method investment loss of ¥53 million.」
For the China hospital operations, profit contribution was scheduled to begin in the fiscal year ending March 2020, and the equity-method investment loss of ¥53 million during the preparation period was presented as an actual result. - FY2018-Q3RestatedAnnual report
「As the impact of this business on the Group’s results is currently uncertain, it has not been incorporated into the current fiscal year earnings forecast.」
The uncertainty that the earnings impact of the China hospital operations remains undetermined and has not been incorporated into the current fiscal year earnings forecast is being reaffirmed. - FY2018-Q2RestatedAnnual report
「As the impact of this business on the Group’s results is currently uncertain, it has not been incorporated into the current fiscal year earnings forecast.」
The uncertainty that the earnings impact of the China hospital operations remains undetermined and has not been incorporated into the current fiscal year earnings forecast is being reaffirmed. - FY2018-Q1First statedAnnual report
「As the impact of this business on the Group’s results is currently uncertain, it has not been incorporated into the current fiscal year earnings forecast.」
The company described the uncertain impact of the China hospital operations on Group results, and the fact that it has not been incorporated into the current fiscal year earnings forecast, as a new risk and uncertainty.